Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)
Table 2
Immunological outcomes based on specific DTH, tetramer, and IFN-γ responses.
Patient Code
DTH responders positive (+) negative (−)
Fold increase in tetramer
Tetramer responders positive (+) negative (−)
Absolute change in IFN-γ
IFN-γ responder positive (+) negative (−)
week 26
week 52
week 26
week 52
UPIN13
+
22.25
34.49
+
141.4
0
+
UPIN16
+
22.77
121.29
+
44.4
241.6
+
UPIN28
+
29.25
12.5
+
525.4
847.9
+
UPIN40
+
15.85
2.47
+
313.5
488.9
+
UPIN45
+
11.39
6.97
+
30.6
88.8
−
UPIN49
+
1.75
1.71
−
0
113.5
+
UPIN50
+
6.11
3.8
+
−20.7
−20.7
−
UPIN51
+
0.69
0.26
−
0
0
−
UPIN53
+
1.58
0.69
−
25.3
2417.4
+
UPIN55
+
2.71
5.28
+
262.7
66
−
UPIN69
+
2.09
0.23
−
1293.5
133.4
+
UPIN71
+
4.91
4.82
+
20.9
31
−
UPIN81
+
1.72
0.09
−
−2.9
−2.9
−
UPIN88
+
1.42
0.06
−
−34.5
230.4
+
UPIN2
−
3.09
5.83
+
63.9
−50.2
−
UPIN21
−
0.51
5.43
+
1064
−9.3
+
UPIN26
−
0.35
0.81
−
255.5
1211.4
+
UPIN27
−
82.11
ND
+
2236
ND
+
UPIN32
−
1.13
1.05
−
0
0
−
UPIN35
−
1.31
0.09
−
−10.4
24.3
+
UPIN37
−
0.80
0.26
−
1.4
0
−
UPIN38
−
10.79
1.37
+
112.1
1.3
+
UPIN43
−
1.11
5.06
+
−3.5
−11.2
−
UPIN67
‒
1.72
0.07
‒
40.3
0
‒
UPIN70
‒
0.46
1.85
‒
130.9
0
+
UPIN82
‒
4.47
0.24
+
‒3.2
‒3.2
‒
UPIN85
‒
2.50
0.08
‒
0
0
‒
UPIN89
‒
2.93
0.02
‒
‒46.9
‒46.9
‒
Fourteen of 28 (50%) patients developed positive tetramer, IFN-γ, and/or DTH responses to PSA146-154 peptide by week 52. A positive tetramer response is defined as ≥4-fold increase in tetramer levels by week 52 over prevaccine levels, while positive IFN-γ response was defined as ≥100 ng/ml of absolute change in cytokine levels at week 26 or 52 minus prevaccine levels. A positive DTH reaction is defined as ≥15 mm of induration to PSA146-154 peptide. A stringent cutoff value was taken into consideration to measure true immune responses and to avoid false positives.
